Summit Therapeutics Inc. Payments to Acquire Intangible Assets
Summit Therapeutics Inc. (SMMT) reported Payments to Acquire Intangible Assets of $0 for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireIntangibleAssets · last filed 2021-08-12
- Summit Therapeutics Inc. payments to acquire intangible assets for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. payments to acquire intangible assets for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. payments to acquire intangible assets for the quarter ending 2020-12-31 was $0.00.
- Summit Therapeutics Inc. payments to acquire intangible assets for the quarter ending 2020-09-30 was -$168.00K, a 4300.00% decline year-over-year.
- Summit Therapeutics Inc. payments to acquire intangible assets for fiscal 2020 was $0.00.
- Summit Therapeutics Inc. payments to acquire intangible assets for fiscal 2019 was $7.00K.
| Period end | Payments to Acquire Intangible Assets 3 month | Payments to Acquire Intangible Assets 6 month | Payments to Acquire Intangible Assets 9 month | Payments to Acquire Intangible Assets 11 month | Payments to Acquire Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-08-12 | -$168.00K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-17 | $0.00 derived: sum of 2 quarters · filed 2021-05-17 | -$168.00K derived: sum of 3 quarters · filed 2021-05-17 | -$164.00K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$168.00K derived: sum of 2 quarters · filed 2021-03-31 | -$164.00K derived: sum of 3 quarters · filed 2021-08-12 | $0.00 10-K · filed 2021-03-31 | |
| 2020-09-30 | -$168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$164.00K derived: sum of 2 quarters · filed 2021-08-12 | $0.00 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $168.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $164.00K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $136.00K 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $4.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | $111.00K 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | $107.00K 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | $7.00K 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | $154.00K 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |